Pfizer(US:PFE) Zheng Quan Shi Bao Wang·2025-09-23 00:07Core Viewpoint - Pfizer plans to acquire weight-loss drug developer Metsera for up to $7.3 billion, which includes $47.50 per share in cash and performance-based milestone payments [1] Group 1: Acquisition Details - The acquisition price consists of cash and contingent payments based on performance milestones [1] - Pfizer's previous efforts in developing its own weight-loss drug, danuglipron, faced setbacks related to tolerability and safety concerns [1] Group 2: Metsera's Profile - Metsera was established in 2022 and is focused on developing obesity treatments based on GLP-1 mechanisms and other targets [1] - The primary candidate drug MET-097i has shown an average weight loss of 11.3% in mid-stage trials [1] Group 3: Market Context - The global weight-loss drug market is projected to reach $150 billion by the early 2030s [1] - Through the acquisition of Metsera, Pfizer aims to quickly acquire a mature drug pipeline to compete against dominant players like Eli Lilly and Novo Nordisk [1]